[PDF][PDF] Oral rivaroxaban in the prophylaxis of COVID-19 induced coagulopathy
D Kumar, V Kaimaparambil… - J Assoc Physicians …, 2022 - researchgate.net
Background: Preliminary data highlights the importance of anticoagulation therapy in the
prevention and treatment of thromboembolism in SARS CoV-2 infection. There is insufficient …
prevention and treatment of thromboembolism in SARS CoV-2 infection. There is insufficient …
Thromboprophylaxis and clinical outcomes in moderate COVID-19 patients: a comparative study
AS Mohamed, HM Ahmad, ASA Abdul-Raheem… - Research in Social and …, 2022 - Elsevier
Background Many thrombotic complications are linked to coronavirus disease 2019 (COVID-
19). Antithrombotic treatments are important for prophylaxis against these thrombotic events …
19). Antithrombotic treatments are important for prophylaxis against these thrombotic events …
[HTML][HTML] Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE–COALITION VIII randomised clinical trial
Á Avezum, HAO Junior, PDMM Neves, LBO Alves… - …, 2023 - thelancet.com
Background COVID-19 progression is associated with an increased risk of arterial and
venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the …
venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the …
[HTML][HTML] Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID …
U Rauch-Kröhnert, M Puccini, M Placzek… - Clinical Research in …, 2023 - Springer
Background COVID-19 is associated with a prothrombotic state. Current guidelines
recommend prophylactic anticoagulation upon hospitalization. Methods COVID-PREVENT …
recommend prophylactic anticoagulation upon hospitalization. Methods COVID-PREVENT …
The impact of anticoagulation on COVID-19 (SARS CoV-2) patient outcomes: a systematic review
D Lazaridis, S Leung, L Kohler… - Journal of …, 2022 - journals.sagepub.com
Background: Emerging data suggest that coagulopathy, cytokine storm, and acute
respiratory distress syndrome are associated with the 2019 coronavirus disease (COVID …
respiratory distress syndrome are associated with the 2019 coronavirus disease (COVID …
Rivaroxaban for prevention of thrombotic events, hospitalization, and death in outpatients with COVID-19: a randomized clinical trial
G Piazza, AC Spyropoulos, J Hsia, M Goldin… - Circulation, 2023 - Am Heart Assoc
Background: COVID-19 (coronavirus disease 2019) is associated with heightened risks of
venous and arterial thrombosis and hospitalization due to respiratory failure. To assess …
venous and arterial thrombosis and hospitalization due to respiratory failure. To assess …
Anticoagulation in COVID-19: current concepts and controversies
A Chandra, U Chakraborty, S Ghosh… - Postgraduate medical …, 2022 - academic.oup.com
Rising incidence of thromboembolism secondary to COVID-19 has become a global
concern, with several surveys reporting increased mortality rates. Thrombogenic potential of …
concern, with several surveys reporting increased mortality rates. Thrombogenic potential of …
Randomized clinical trial to evaluate a routine full anticoagulation strategy in patients with coronavirus infection (SARS-CoV2) admitted to hospital: rationale and …
RD Lopes, RHM Furtado, AVS Macedo… - American heart …, 2021 - Elsevier
Background Observational studies have suggested a higher risk of thrombotic events in
patients with coronavirus disease 2019 (COVID-19). Moreover, elevated D-dimer levels …
patients with coronavirus disease 2019 (COVID-19). Moreover, elevated D-dimer levels …
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
WH Capell, ES Barnathan, G Piazza… - American heart …, 2021 - Elsevier
Background COVID-19 is associated with both venous and arterial thrombotic complications.
While prophylactic anticoagulation is now widely recommended for hospitalized patients …
While prophylactic anticoagulation is now widely recommended for hospitalized patients …
[HTML][HTML] Anticoagulant treatment in severe ARDS COVID-19 patients
A Ceccato, M Camprubí-Rimblas… - Journal of clinical …, 2022 - mdpi.com
Patients with COVID-19 may complicate their evolution with thromboembolic events.
Incidence of thromboembolic complications are high and also, patients with the critically-ill …
Incidence of thromboembolic complications are high and also, patients with the critically-ill …